The promise of long-acting PrEP has been super-charged this year by studies showing the powerful efficacy of an antiretroviral known as lenacapavir (LEN).  This episode of PxPulse goes deep on LEN for PrEP. Recorded just days before Gilead’s announcement

A list of tactics proved critical; establishing a dedicated working group that brought in diverse expertise and support; ensuring there were educated and committed policy leaders in government; and supporting community members to be ready to lead. Addit

On this episode of the Advocacy Chronicles: A look at advocacy in Uganda for the Dual Prevention Pill (DPP), a new product combining oral PrEP and oral contraception.Ruth Akulu is a member of the DPP Civil Society Advisory Group, part of the Uganda Cou

In this episode, Nsubuga Allan Mwasa a Ugandan activist, a clinical psychologist, and a representative of Sexual Minorities Uganda, or SMUG, an organization that has been at the forefront of the fight for LGBTQ rights, talks about how advocates are orga

Its considered one of the most important and most difficult scientific enterprises in the history of modern medicinethe hunt for an HIV vaccine. It has led to vast knowledge of HIV and the immune system, and to breakthrough technology. But developing a

Our debut episode of the Advocacy Chronicles features Yvette Raphael, the Executive Director of Advocacy for Prevention of HIV and AIDS (APHA) in South Africa, and a leader in the development of The Choice Manifesto, supported from start to finish by CASP

In this episode of PxPulse, we talk about why and how the decisions that shape global health must be made by those facing the greatest risks. As the world evaluates the pandemic response and debates on decolonizing global health gain momentum, equity in g

People who are pregnant or lactating (PLP) have historically been excluded from research because of concerns for the developing fetus. But this has led to a dearth of data on new interventions against health threats for this population. In the case of HIV

2023 is a big year for PEPFAR. PEPFARs considered one of the greatest US foreign policy and global development achievements of the century; the program has saved upwards of 25 million lives since it launched in 2003. But PEPFAR is marking its 20th anni

With several large HIV vaccine trials in the last few years finding no efficacy, the field is in transition. There are diverse ideas in vaccine research, but there's no clear concept that's ready to test in a late-phase trial or move toward product develo